Ghada Ezat Hammoda1, Sally Mohammed El-Hefnawy2, Asmaa Gaber Abdou3, Rania Abdallah Abdallah4. 1. Assistant Professor, Department of Medical Biochemistry, Menoufia University , Shebein Elkom, Menoufia, Egypt . 2. Lecturer, Department of Medical Biochemistry, Menoufia University , Shebein Elkom, Menoufia, Egypt . 3. Professor, Department of Pathology, Menoufia University , Shebein Elkom, Menoufia, Egypt . 4. Lecturer, Department of Pathology, Menoufia University , Shebein Elkom, Menoufia, Egypt .
Abstract
INTRODUCTION: Breast cancer is the most common cancer in women and the Erythroblastosis Oncogene B(ErbB) receptor family holds crucial role in its pathogenesis. Human Epidermal Growth Factor Receptor 3 (HER-3) gene over expression in breast tissue has been associated with aggressive clinical behaviour and bad prognosis. AIM: To evaluate HER-3 mRNA expression level as a prognostic marker for breast cancer and to correlate its level with other established prognostic parameters. MATERIALS AND METHODS: This study was carried out on specimens of 100 cases that were divided into 40 patients presented with fibroadenoma and 60 patients presented with Invasive Ductal Carcinoma (IDC) not otherwise specified and underwent modified radical mastectomy. All specimens were investigated for HER-2/neu, ER and PR expression by Immunohistochemistry (IHC) and quantitative assay of HER-3 mRNA expression using real time PCR technique. RESULTS: There was a significant high HER3 mRNA level in carcinoma cases compared to fibroadenoma. In malignant cases, HER3 mRNA level was significantly associated with advanced T stage, advanced N stage, number of positive lymph nodes, large tumour size and cases associated with an adjacent in situ component. Moreover, HER-3 mRNA level was of highest values in Her-2/neu positive group followed by triple negative cases with the lowest level in luminal group (p<0.05). CONCLUSION: HER-3 gene is upregulated in IDC especially those carrying poor prognostic features. HER-3 mRNA level may identify a subset of patients with a poor prognosis, and who could undergo further evaluation for the efficacy of HER3 targeted anticancer therapy.
INTRODUCTION:Breast cancer is the most common cancer in women and the Erythroblastosis Oncogene B(ErbB) receptor family holds crucial role in its pathogenesis. Human Epidermal Growth Factor Receptor 3 (HER-3) gene over expression in breast tissue has been associated with aggressive clinical behaviour and bad prognosis. AIM: To evaluate HER-3 mRNA expression level as a prognostic marker for breast cancer and to correlate its level with other established prognostic parameters. MATERIALS AND METHODS: This study was carried out on specimens of 100 cases that were divided into 40 patients presented with fibroadenoma and 60 patients presented with Invasive Ductal Carcinoma (IDC) not otherwise specified and underwent modified radical mastectomy. All specimens were investigated for HER-2/neu, ER and PR expression by Immunohistochemistry (IHC) and quantitative assay of HER-3 mRNA expression using real time PCR technique. RESULTS: There was a significant high HER3 mRNA level in carcinoma cases compared to fibroadenoma. In malignant cases, HER3 mRNA level was significantly associated with advanced T stage, advanced N stage, number of positive lymph nodes, large tumour size and cases associated with an adjacent in situ component. Moreover, HER-3 mRNA level was of highest values in Her-2/neu positive group followed by triple negative cases with the lowest level in luminal group (p<0.05). CONCLUSION:HER-3 gene is upregulated in IDC especially those carrying poor prognostic features. HER-3 mRNA level may identify a subset of patients with a poor prognosis, and who could undergo further evaluation for the efficacy of HER3 targeted anticancer therapy.
Entities:
Keywords:
Breast cancer; Molecular subtypes; Radical mastectomy
Authors: M Aubele; G Auer; A K Walch; A Munro; M J Atkinson; H Braselmann; T Fornander; J M S Bartlett Journal: Br J Cancer Date: 2007-02-13 Impact factor: 7.640
Authors: Xiu-Rong Ren; Jiangbo Wang; Takuya Osada; Robert A Mook; Michael A Morse; Larry S Barak; Herbert Kim Lyerly; Wei Chen Journal: Breast Cancer Res Date: 2015-02-15 Impact factor: 6.466
Authors: A Travis; S E Pinder; J F Robertson; J A Bell; P Wencyk; W J Gullick; R I Nicholson; D N Poller; R W Blamey; C W Elston; I O Ellis Journal: Br J Cancer Date: 1996-07 Impact factor: 7.640
Authors: Kelly A Hirko; Amr S Soliman; Ahmed Hablas; Ibrahim A Seifeldin; Mohamed Ramadan; Mousumi Banerjee; Joe B Harford; Robert M Chamberlain; Sofia D Merajver Journal: J Cancer Epidemiol Date: 2013-10-24